A method was developed and fully validated for the determination of bevantolol, an adrenergic-receptor blocker, in human plasma. Bevantolol and betaxolol as internal standard (I.S) were extracted from 1mL of human plasma by solid phase extraction technique using Sep-pak silica cartridge. Chromatographic separation was accomplished under isocratic conditions using a reverse-phase C8 analytical column and mixture of dibasic ammonium phosphate (pH 5.7; 50mM)-acetonitrile (75:25, v/v) as mobile phase, with a detection wavelength at 220 nm. The method was proved to be specific by testing six different human plasma sources. Linearity was established for the concentration ranges of 40-1600 ng/mL with correlation coefficent of 0.9995. The lower limit of quantification 40 ng/mL with precision of 10.9% as C.V%.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Duke, I. D. and Williams, E. M., Cardiovascular effects of bevantolol, a selective β1-adrenoceptor antagonist with a novel pharmacological profile.Br. J. Pharmacol., 84, 365–380 (1985).
Guidance for industry. Bioanalytical Method Validation. U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)(2001).
Guidance for industry. Bioavailability and Bioequivalence Studies for orally Administered Drug Products: General Considerations. U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2003).
Hastings, S. G, Smith, R. D., Corey, R. M., Essenburg, A. D., Pettway, C. E., and Tessman, D. K., Pharmacologic evalution of CI-775, a cardioselective beta-adrenergic antagonist.Arch. Int. Pharmacodyn., 226, 81–99 (1977).
Hoefle, M. L, Hastings, S. G, Meyer, R. F., Corey, R. M., Holmes, A., and Stratton, C. D., Cardioselective beta-adrenergic blocking agents. 1: 1-[(3,4-dimethoxyphenethyl)-amino]-3-aryloxy-2-propanols.J. Med. Chem., 18, 148–152 (1975).
Lofdahl, C, Svedmyr, K., and Svedmyr, N., Selectivity of bevantolol hydrochloride, a β1-adrenoceptor antagonist, in asmatic patient.Pharmacotherapy, 4, 205–210 (1984).
Mackay, A. D., Gribbin, H. R., Baldwin, C. J., and Tattersfield, A. E., Assessment of bronchial beta-blockade after oral bevantolol.Clin. Pharmacol. Ther, 29, 1–6 (1981).
Nation, R. L, Peng, G W., and Chiou, W. L, High pressure liquid Chromatographic method for simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma.J. Chromatogr., 145, 429–436 (1978).
Pico, Y, Blasco, C, and Font, G, Environmental and food applications of LC-tandem mass spectrometry in pesticideresidue analysis: an overview.Mass Spectro. Reviews, 23, 45–85 (2004).
Randinitis, E. J., Nelson, C., and Kinkel, A. W., Gas chromatographic determination of bevantolol in plasma.J. Chromatogr., 308, 345–349 (1984).
Selen, A, Kinkel, A. W., Darke, A. C, Greene, D. S, and Welling, P. G, Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.Eu. J. Clin Pharmacol, 30, 699–704 (1986).
Steen, S. N., Smith, R. L, Ginzton, L. E., and Criley, J. M., Bevantolol in treatment of anagina pectoris.Chest, 76, 368 (1979).
Steen, S. N., Smith, R. L, Ginzton, L. E., Criley, J. M., and Blouin, L. T., Bevantolol as long-term antianginal therapy.Pharmacologist, 22, 191 (1980).
Steven, E. R. and Randinitis, E. J., A high-performance liquid Chromatographie assay for the enantiomers of bevantolol in human plasma.Pharm. Research, 8, 758–762 (1991).
Vermeij, P. and Brummelen, P. V, Pharmacokinetic parameters of bevantolol in volunteers.EurJ. Clin. Pharmacol., 30, 375–377 (1986).
Yamamoto, M., Takayanagi Y, Nihashi, S., Nomura, Y, and Nohira, H., Bevantolol hydrochloride (nc-1400): Absolute configuration and direct separation of the enantiomers.Chirality 7, 572–574 (1995).
About this article
Cite this article
Trung, T.Q., Long, P.H., Al-Abd, A.M. et al. Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res 30, 890–897 (2007). https://doi.org/10.1007/BF02978842